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Osteosarcoma (OS) is an aggressive bone tumor primarily affecting chil-
dren and adolescents. The etiology of OS is not fully understood. Thus,
there is a great need to obtain a better understanding of OS development
and progression. Alterations in miRNA expression contribute to the
required molecular alterations for neoplastic initiation and progression.
This study is the first to investigate miRNA expression in OS in a large dis-
covery and validation cohort comprising a total of 101 OS samples. We
established the signature of altered miRNA expression in OS by profiling
the expression level of 752 miRNAs in 23 OS samples using sensitive
LNA-enhanced qPCR assays. The identified miRNA expression changes
were correlated with gene expression in the same samples. Furthermore,
miRNA expression changes were validated in a second independent cohort
consisting of 78 OS samples. Analysis of 752 miRNAs in the discovery
cohort led to the identification of 33 deregulated miRNAs in OS. Twenty-
nine miRNAs were validated with statistical significance in the second
cohort comprising 78 OS samples. miRNA/mRNA targets were deter-
mined, and 361 genes with an inverse expression of the target miRNA were
identified. Both the miRNAs and the identified target genes were associated
with multiple pathways related to cancer as well as bone cell biology,
thereby correlating the deregulated miRNAs with OS tumorigenesis. An
analysis of the prognostic value of the 29 miRNAs identified miR-221/
miR-222 to be significantly associated with time to metastasis in both
cohorts. This study contributes to a more profound understanding of OS
tumorigenesis, by substantiating the importance of miRNA deregulation.
We have identified and validated 29 deregulated miRNAs in the – to our
knowledge – largest discovery and validation cohorts used so far for
miRNA analyses in OS. Two of the miRNAs showed a promising potential
as prognostic biomarkers for the aggressiveness of OS.
Abbreviations
FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded; HE, hematoxylin/eosin; IPA, Ingenuity Pathway Analysis; KEGG, Kyoto
Encyclopedia of Genes and Genomes; miRNA, microRNA; MSC, mesenchymal stem cell; OB, osteoblast; OS, osteosarcoma; PCA, principal
component analysis; QC, quality control; UTR, untranslated region.
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1. Introduction
Osteosarcoma (OS) is an aggressive tumor of the
bone most frequently affecting children and adoles-
cents. OS is often diagnosed at a very late stage, as
the first indication of the malignancy is pain, which
is often mistaken for more common conditions such
as ‘growing pains’ (McCarville, 2009). The late identi-
fication of OS leads to 15–25% of the patients
exhibiting distant metastases at the time of diagnosis
(Bielack et al., 2002). The five-year survival rate of
OS patients with no detectable metastases at the time
of diagnosis is 65–70% (Bielack et al., 2002), whereas
patients with relapsing disease or detectable metas-
tases at the time of diagnosis have only a five-year
survival rate of 10–40% (Kager et al., 2003; Meyers
et al., 1993).
OS is characterized by diverse cytogenetic alterations
and exhibits changes in multiple different pathways
with substantial cell-to-cell variation (Bridge et al.,
1997). The etiology of OS is not well understood and
the only prognostic markers are the absence of metas-
tases at the time of diagnosis and the response to
neoadjuvant chemotherapy measured as the extent of
tumor necrosis (Wang, 2005). However, the character-
istic onset of high-grade neoplasms in young people
indicates a consistent, but yet undetected, alteration or
group of alterations defining OS.
Cancer initiation and progression is controlled by
both genetic and epigenetic events (Hanahan and
Weinberg, 2011). Epigenetic changes are particularly
important for childhood cancers, which are often char-
acterized by a low mutational load. Molecular sub-
types, clinical heterogeneity, and in some cases the
prediction of the disease course have been associated
with epigenetic changes. This has been demonstrated
for ependymomas (Mack et al., 2014) and more
recently Ewing sarcoma (Sheffield et al., 2017), which
are characterized by no or the same recurrent genetic
aberration, respectively. The genetic components of
OS have been intensively studied (Bishop et al., 2016;
Kansara et al., 2014); however, the elucidation of the
epigenetic changes is still in its early stage. Gene
expression is regulated by numerous mechanisms and
molecules, including microRNAs (miRNAs). These are
small noncoding RNA molecules (22–25 nucleotides),
regulating gene expression post-transcriptionally by
blocking mRNA translation and/or altering the stabil-
ity of the mRNA by binding perfectly or with mis-
matches to the 30-untranslated region (UTR) of the
mRNA (Stark et al., 2003). Each miRNA can poten-
tially directly or indirectly regulate more than 100
target genes and thereby affect the expression of both
tumor suppressors and oncogenes (Brennecke et al.,
2005). Furthermore, miRNAs function as classical
tumor suppressors and oncogenes/oncomiRs as specific
miRNA alterations are associated with carcinogenesis.
Deregulation of miRNA expression has been identified
in numerous cancers emphasizing the importance of
miRNAs in carcinogenesis and their potential as diag-
nostic, prognostic, and therapeutic means (Calin and
Croce, 2006; Negrini et al., 2009).
miRNAs are also important regulators of osteogenic
signaling pathways and are implicated in normal
osteoblast (OB) growth and differentiation (Inose
et al., 2009; Lian et al., 2012). Hence, changes in this
balance will affect proliferation of bone cells and may
contribute to OS development. The impact of alter-
ations in miRNA expression patterns in OS develop-
ment has been addressed in several studies (Duan
et al., 2011; Jones et al., 2012; Lulla et al., 2011;
Maire et al., 2011; Namlos et al., 2012; Thayanithy
et al., 2012; Won et al., 2013; Zhang et al., 2015).
However, none of the results are consistent across the
studies, which may reflect different methodologies and
normalization strategies, as well as low sample num-
bers. Most studies have evaluated a single miRNA,
but a few studies have established a miRNA expres-
sion profile of OS by profiling several hundred miR-
NAs (Duan et al., 2011; Jones et al., 2012; Lulla et al.,
2011; Maire et al., 2011; Namlos et al., 2012; Won
et al., 2013; Zhang et al., 2015). However, all studies
have analyzed a limited number of OS samples ranging
from 2 to 18.
In this study, we established the signature of
miRNA expression alterations in OS by profiling the
expression of 752 miRNAs in 23 OS samples using a
highly sensitive qPCR technology. Significantly deregu-
lated miRNAs were validated in an independent
cohort comprising 78 OS samples. Both the miRNAs
and identified target mRNAs were evaluated for their
relation to cancer development and progression, as
well as bone cell biology.
2. Materials and methods
2.1. OS samples
Fresh-frozen diagnostic biopsies of primary tumors
from 23 patients diagnosed with OS were collected
from the archives of the Institute of Pathology, Aarhus
University Hospital (Table 1). The biopsies were
immediately snap-frozen and stored at 80 °C. 25–50
tissue sections of 10 lm were used for RNA extraction
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for each sample. Tissue sections were hematoxylin/
eosin (HE)-stained for every fifth 10-lm tissue section
cut to confirm the presence of tumor cells.
Formalin-fixed, paraffin-embedded (FFPE) samples
from 78 primary tumors from patients diagnosed with
OS were collected from the archives of the Institute of
Pathology, Aarhus University Hospital (Table 1). A
complete outline of the different procedures and analy-
ses performed with each cohort is shown in Fig. 1.
The Local Ethical Committee, The Central Den-
mark Region, approved this study (journal number
1-10-72-521-12).
2.2. Cell lines
Five OS and three OB cell lines were used in this
study. The OS cell lines CRL-1543, CRL-1427, CRL-
2098, HTB-85, and HTB-96 and the OB cell line CRL-
11372 were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). The OB cell
line C-12720 was purchased from PromoCell (Heidel-
berg, Germany), and the OB cell line HO-f-4610 was
purchased from SanBio (Uden, The Netherlands).
HTB-96 and HTB-85 were cultured in McCoy’s 5a
medium modified. CRL-1427 and CRL-1543 were cul-
tured in Eagle’s minimum essential medium. CRL-
2098 was cultured in RPMI-1640. All OS cell lines
were supplemented with 40 mgmL1 streptomycin,
240 mgmL1 penicillin (400 000 UmL1), and 10%
fetal bovine serum, except for HTB-85, which was sup-
plemented with 15% fetal bovine serum. CRL-11372
was cultured in 1 : 1 mixture of Ham’s F12 medium
and Dulbecco’s modified Eagle’s medium without phe-
nol red, supplemented with 0.3 mgmL1 G-418 and
10% fetal bovine serum. C-12720 was cultured in OB
growth medium + supplement mix (PromoCell). HO-f
was cultured in OB medium (ScienCell Research Labo-
ratories, Carlsbad, CA, USA), and the flasks were
coated with poly-L-lysine solution bioreagent 0.01%
(Sigma Aldrich, St Louis, MO, USA).
All eight cell lines were cultured in a humidified
atmosphere of 5% CO2 at 37 °C, except for CRL-
11372, which was cultured at 34 °C.
2.3. Total RNA extraction from fresh-frozen OS
samples and cell lines
Total RNA including miRNAs was extracted from the
23 fresh-frozen OS samples and the eight cell lines.
The tissue was homogenized using a TissueLyser bead
mill and one tungsten carbide bead (3 mm) per sam-
ple. RNA extraction was performed using the miR-
Neasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions until each sample
was separated into three phases. The upper aqueous
phase was transferred to a new tube and total RNA
Table 1. Clinical and pathological data for 23 fresh-frozen and 78
FFPE primary OS samples analyzed.
Patient characteristics
Number of patients (%)
Discovery
cohort
Validation
cohort
Total 23 (100) 78 (100)
Gender
Male 11 (48) 43 (55)
Female 12 (52) 35 (45)
Age (years)
Median age 17 25.0
Mean age 27.9 32.0
Range 9–76 5–82
Primary site
Femur 8 (35) 27 (35)
Tibia 10 (44) 22 (28)
Fibula 1 (4) 2 (2)
Others 4 (17) 27 (35)
Metastasis at diagnosis
Yes 8 (35) 33 (42)
No 15 (65) 45 (58)
Histology
Osteoblastic 9 (39) 30 (39)
Chondroblastic 9 (39) 22 (28)
Telangiectasic 3 (13) 4 (5)
Othera 2 (9) 22 (28)
Chemotherapy treatment
< 40 years: Cisp., doxo., meth. 15 (65) 44 (56)
> 40 years: Cisp., doxo. 2 (9) 7 (9)
Unknown 6 (26) 27 (35)
Tumor necrosis after chemotherapy
Good responders (> 90% necrosis)b 9 (39) 17 (22)
Poor responders (< 90% necrosis)c 8 (35) 34 (43)
Unknown 6 (26) 27 (35)
Survival (months)
Mean survival 75.5 81.7
Range 1–175 1–282
Long-term survival
< 5 years 7 (30) 30 (39)
> 5 years 12 (52) 42 (54)
Not evaluatedd 4 (18) 6 (7)
Type of sample analyzed
Biopsy 23 (100) 66 (85)
Larger tumor specimen 0 (0) 12 (15)
Cisp., cisplatin; doxo., doxorubicin; meth., methotrexate.
a All OS samples were high-grade tumors except for two of the
FFPE samples, which were parosteal OS.
b Of the good responders, one patient in the discovery cohort and
one in the validation cohort were > 40 years.
c Of the poor responders, one patient in the discovery cohort and
six in the validation cohort were > 40 years.
d Patients with < 5 years since diagnosis or who died of other
causes than OS.
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Discovery Cohort 
23 OS samples (Fresh frozen) 
Normal control: 3 OB cell lines 
Validation Cohort 
78 OS samples (FFPE) 
Normal control: 3 OB cell lines 
Cohorts 
RNA extraction 
cDNA synthesis 
Quality control 
miRNA analysis 
Data analysis 
miRNeasy Mini Kit (Qiagen) miRNAeasy FFPE Kit (Qiagen) 
50 ng RNA 
Universal cDNA Synthesis Kit II (Exiqon) 
65 ng RNA 
Universal cDNA Synthesis Kit II (Exiqon) 
QC of cDNA
Expression of: miR-103; miR-191-5p; 
miR-423 (Cq<32) 
UniSp6 (Spike-in) (Cq:16-18) 
QC of cDNA
Expression of: miR-191-5p;  
miR-423-5p (Cq<30);  
UniSP4, UniSp5, UniSp6 (Spike-ins) 
752 miRNAs analysed
microRNA Ready-to-Use PCR,  
Human Panel I+II v2 (Exiqon) 
cDNA diluted 1:100 
33 miRNAs analysed
Pick&Mix microRNA  
PCR Panels (Exiqon) 
cDNA diluted 1:20 
Analysis in GenEx Software (MultiD) 
Normalization: Mean global expression 
Analysis in GenEx Software (MultiD) 
Normalization: 5 reference miRs
78 miRs diff. expressed  
(OS samples vs OB cell lines) 
5 reference miRs
identified 
29 miRs diff. expressed 
(OS samples vs OB cell lines) 
33 miRs diff. expressed 
Exclusion of miRs with no expr. diff.  
btw. OS cell lines and OB cell lines 
Results 
Fig. 1. A detailed outline of the different processes and analyses performed for the OS discovery and validation cohort. QC, quality control;
diff., differential; btw., between.
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was purified using a QIAcube automated device (Qia-
gen) according to the manufacturer’s instructions
including an on-column DNase digest. RNA was
quantified using a NanoDrop ND-2000c spectropho-
tometer (Thermo Fisher Scientific, Waltham, MA,
USA), and the quality was assessed using the RNA
6000 Nano Kit (Agilent Technologies Inc., Santa
Clara, CA, USA) on an Agilent 2100 BioAnalyzer.
2.4. RNA extraction from FFPE samples
Four tissue sections of 10 lm from each FFPE sample
were used for RNA extraction. RNA was extracted
using the miRNeasy FFPE Kit (Qiagen) according to
the manufacturer’s instructions (Fig. 1). One microlitre
Spike-in (UniSp2, UniSp4, and UniSp5), from the RNA
Spike-in kit, UniRT (Exiqon, Vedbæk, Denmark), was
added to the PKD buffer during the purification.
2.5. cDNA synthesis and miRNA expression
analysis of fresh-frozen OS samples
For the initial miRNA profiling analysis, 50 ng of total
RNA from 23 fresh-frozen OS samples, two OS, and
three OB cell lines was reverse-transcribed using the
miRCURY LNATMUniversal RT microRNA PCR kit
(Exiqon) in a Mastercycler pro S (Eppendorf, Ham-
burg, Germany) in a 50 lL reaction volume, comprising
the Universal cDNA synthesis kit II, RNA Spike-in kit
(Exiqon) (Fig. 1). Quality control (QC) was performed
according to the manufacturer’s instructions using the
ExiLENT SYBR Green master mix kit (Exiqon), using
1 : 80 diluted cDNA. Quality of the cDNA synthesis
and PCR amplification were evaluated through the
detection of miR-103, miR-191-5p, miR-423, and
UniSp6 at stable Cq levels (Cq < 32) (Fig. 1).
The miRNA profile was established using 45 ng
cDNA from each sample by qPCR using the micro-
RNA Ready-to-Use PCR, Human panel I and panel
II v2 analyzing 752 miRNAs (Exiqon) on a Lightcy-
cler 480 V2 Real-Time PCR System (Roche Applied
Science, Penzberg, Germany) (Fig. 1). The plates were
set up using a Bravo Automated Liquid Handling
Platform (Agilent Technologies Inc.).
2.6. Validation of miRNA expression in OS FFPE
samples
A total of 65 ng RNA (5 nglL1) from the OS FFPE
samples and the cell lines was reverse-transcribed in
20 lL reactions using the Universal cDNA Synthesis kit
II (Exiqon) and a 2720 Thermal Cycler (Thermo Fisher
Scientific) (Fig. 1). Reverse transcription was performed
in duplicate for each sample. All the subsequent amplifi-
cations were performed using a Lightcycler 480 Real-
Time PCR System (Roche Applied Science). QC of the
cDNA synthesis and PCR amplification were performed
according to the manufacturer’s instructions (Exiqon),
with slight modifications; the cDNA was diluted 1 : 20
to ensure the detection of lowly expressed miRNAs.
Spike-ins were included in the RNA purification and
RT step using the RNA Spike-in kit, UniRT (Exiqon).
hsa-miR-191-5p, hsa-miR-423-5p, UniSp4, UniSp5,
UniSp6, and Cel-miR-39-3p were used for QC of the
RNA purification and cDNA synthesis (Fig. 1). UniSp4
and UniSp5 RNA spike-in controls were used for QC of
RNA purifications. All primary OS FFPE samples,
except one, had Cq values < 37 for UniSp5. UniSp6 and
Cel-miR-39-3p spike-in control primers were used for
QC of the cDNA synthesis and to rule out PCR inhibi-
tion, as a higher concentration of cDNA was used in the
analysis, than described in the manufacturer’s instruc-
tions (65 ng RNA instead of 20 ng for the cDNA syn-
thesis and 1 : 20 dilution of the cDNA instead of
1 : 100). These conditions were optimized for these
amounts to ensure adequate amplification from the
FFPE samples. All primary OS FFPE samples had Cq
values between 16.5 and 18 for UniSp6. Negative con-
trols included in the cDNA synthesis were a no RNA
template and a no RT enzyme.
miRNA expression analysis was performed for 78
FFPE primary OS samples, five OS, and the three OB
cell lines using 5 lL 1 : 20 diluted cDNA from each sam-
ple using a custom Pick&Mix microRNA PCR Panel,
384 well Ready-to-Use (Exiqon) (Fig. 1). Five reference
miRNAs, hsa-miR-148b-3p, hsa-miR-185-5p, hsa-miR-
191-5p, hsa-miR-423-5p, and hsa-miR-425-3p, were
selected based on the results from the discovery cohort,
using both geNorm (Vandesompele et al., 2002) and
NormFinder (Andersen et al., 2004). All 78 OS FFPE
samples had Cq values < 30 for the reference miRNAs.
2.7. Gene expression analysis
Genomic RNA expression analysis was performed
using the SurePrint G3 Human 8X60K One color
Microarrays (Agilent), which analyzes 27958 Entrez
Gene RNAs and 7419 lincRNAs. Hundred nanogram
RNA from each sample of the 23 fresh-frozen OS pri-
mary tumors, five OS cell lines, and three OB cell lines
was analyzed as per the manufacturer’s instructions.
The Agilent G3 Microarrays were scanned using the
NimbleGen MS200 scanner with Multi-TIFF as File
Settings Control, a single scan area was selected, and
the entire feature area was captured. Two-micrometre
resolution was selected. The red channel was omitted
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from the analysis. Grid alignment was determined
manually. Data were extracted using the Agilent Fea-
ture Extraction 11.5.1.1. The raw data were prepro-
cessed using ArrayStar v12.1.0 build 134 (DNASTAR,
Madison, WI, USA) and normalized using the quantile
normalization method and log2-transformed. Genes
were considered differentially expressed when the dif-
ference between OS samples and OB cell lines was > 2-
fold and with a Bonferroni-corrected P-value < 0.05.
Only genes with an average normalized probe intensity
of log2 > 6 in OB cell lines were considered expressed.
2.8. Data analysis
miRNA expression analysis was performed using the
GENEX software version 5.4.2.128 (MultiD, G€oteborg,
Sweden). Raw data (Cq values) for the 752 miRNAs
analyzed using the discovery cohort were imported and
merged (Table S1). Each sample has been run with two
384-well plates containing different miRNAs. Hence,
the raw data contain numerous NA values for the miR-
NAs not present in the respective plates. The mean glo-
bal expression was used for normalization of the
Human Panel I+II v2. The limit for a detectable miRNA
was set to Cq < 37. Log2-normalized data are available
in Table S2. Pick&Mix microRNA PCR Panels were
normalized using five selected stably expressed reference
genes (hsa-miR-148b-3p, hsa-miR-185-5p, hsa-miR-
191-5p, hsa-miR-423-5p, and hsa-miR-425-3p) (Fig. 1).
Raw data (Cq values) for the 33 miRNAs analyzed in
the validation cohort are available in Table S3. The raw
data have been imported and merged using the GENEX
software version 5.4.2.128 (MultiD). Log2-normalized
data for the validation cohort are available in Table S4.
The statistical software R v.3.0.0 (R Core Team
2013) was used for unsupervised hierarchical clustering
using the ‘Ward’ method as distance measure with an
in-house-developed script. Pathway and network anal-
yses were performed using Ingenuity Pathway Analy-
sis (IPA; Qiagen), the Kyoto Encyclopedia of Genes
and Genomes (KEGG) (Kanehisa and Goto, 2000;
Kanehisa et al., 2014), and DIANA miRPath.v3 (Vla-
chos et al., 2015). For the IPA core analysis, the
KEGG pathway analysis, and the DIANA pathway
analysis, human was selected as the species analyzed.
Validated miRNA gene targets were established
using miRWalk2.0 (Dweep and Gretz, 2015) with the
identification of miRNA binding sites in the 30UTR.
The generated gene lists of validated miRNA gene tar-
gets were compared with a list of genes comprising
> 2-fold change (P-value < 0.05) in expression between
23 OS samples and three OB cell lines using Venn
analysis (G. B. Andersen, T. E. Kjeldsen, F. Busato,
C. Dong, J. Q. D. Tran, A. Daunay, D. B. Hussmann,
F. Jehan, V. Geoffroy, J. F. Deleuze, H. Hager, E.
Willerslev, L. L. Hansen & J. Tost, in preparation).
Boxplots, Mann–Whitney U-tests, and Kaplan–Meier
analysis were made with the GRAPHPAD PRISM 7 Soft-
ware (GraphPad Software Inc., La Jolla, CA, USA).
For Kaplan–Meier analysis, the log-rank (Mantel–
Cox) test was used for the determination of P-values.
For the prognostic analyses (survival and time to
metastasis), median expression was used to subdivide
the samples into high and low expression groups.
2.9. Data accessibility
All miRNA data generated and analyzed during this
study are included in this published article (Tables S1–
S4 including both raw and log2-normalized data). The
normalized log2 expression data for the 361 genes ana-
lyzed in this study are provided in Table S5. The raw
gene expression dataset used in the current study is
part of another ongoing study and will be published
and deposited in a public repository separately. Mean-
while, these data are available from the corresponding
author upon request.
3. Results
In the present study (Fig. 1), we investigated changes in
miRNA expression of 752 miRNAs in primary OS and
OS cell lines compared to the miRNA expression levels
of OB cell lines. OB cell lines were used as a reference as
OBs/osteoprogenitor cells are considered to represent
the cell of origin for OS (Abarrategi et al., 2016). The 33
miRNAs identified as differentially expressed in the OS
discovery cohort were validated in an independent vali-
dation cohort comprising 78 primary OS samples.
3.1. Overall miRNA expression
The relative expression levels of 752 miRNAs were
evaluated in 23 primary OS samples, two OS, and
three OB cell lines. Following normalization, using the
global mean, a total of 339 and 202 miRNAs were
reliably detected in more than 40% and 90% of the
samples, respectively. The frequency of missing data
was calculated based on all samples (both OS samples
and OB cell lines). Further analyses were performed
using the dataset with the expression of 339 miRNAs
to ensure analysis of all miRNAs important for OS
etiology. If using a 90% threshold, miRNAs not
expressed in OB cell lines or miRNAs downregulated/
depleted in OS samples could be removed, thereby
excluding biologically relevant miRNAs.
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An unsupervised hierarchical clustering was per-
formed using the log2-transformed expression values
for the 339 miRNAs (Fig. 2). The samples separated
into two main clusters, of which one contained 17 OS
samples and the two OS cell lines. Even though the
OS cell lines were in a cluster with OS samples, the cell
lines kept the closest mutual resemblance, indicating a
cell line similarity stronger than the cell origin. The
other cluster contained six OS samples and the three
OB cell lines. There was no difference between tumor
content or tumor/patient characteristics in these six OS
samples compared with the rest of the OS cohort.
The two observed clusters could not be explained
with the available clinical and histopathological data
as no separation in terms of the primary tumor site,
histology, age, gender, or metastatic status was
observed, even though a smaller group containing five
OS samples separated from the other OS samples
(Fig. S1). These samples had a slightly higher miRNA
detection level, which might explain the separation. Of
note, these samples were different from the six OS
samples grouping apart in the cluster.
3.2. Identification of differentially expressed
miRNAs in OS
When comparing expression profiles between OS sam-
ples and OB cell lines, 76 miRNAs were identified as
differentially expressed (P-value < 0.05) (Table S6). As
OB cell lines were used as the normal control,
miRNAs with no expression change between OS and
OB cell lines were excluded to avoid expression
changes caused by cell culture and not as a result of
cell origin. This provided a list of 33 miRNAs with
deregulated expression levels, of which 26 were signifi-
cantly downregulated and seven were upregulated in
the OS samples compared to OB cell lines (Table 2,
Fig. 3 and Fig. S2A,B). Four of these miRNAs (miR-
181a-5p, miR-181b-5p, miR-30e-3p, and miR-92b-3p)
did not exhibit an expression difference between OS
and OB cell lines, but were, nonetheless, selected for
further validation as miR-181a-5p, miR-181b-5p, and
miR-92b-3p have previously been associated with OS
development and miR-30e-3p has been shown to be
deregulated in several other cancers (Duan et al.,
2011; Jones et al., 2012; Ning et al., 2016; Zhu et al.,
2014). Of the 33 differentially expressed miRNAs, 12
miRNAs have not previously been described as differ-
entially expressed in OS (Table S7). Of the previously
described miRNAs, 16 were identified with the same
direction of the expression change as in this study,
while five miRNAs showed an opposite expression
change (Table S7). On the other hand, previous stud-
ies using microarrays or sequencing to investigate
miRNA expression changes in OS identified 14 miR-
NAs, which were not part of the 33 validation miRNAs
found in this study (each miRNA was identified in
three or more studies) (Table S8). However, 10 of the
miRNAs were identified as both up- and downregu-
lated in different profiling studies. A further
OS18
OS22
OS21
OS20
OS8
OS17
OS2
OS13
OS23
OB Cell Line 2
OB Cell Line 3
OB Cell Line 1
OS10
OS15
OS14 Duplicate 1
OS14 Duplicate 2
OS6
OS16
OS5
OS7
OS19
OS3
OS11
OS9
OS4
OS12
OS1
OS Cell Line 1
OS Cell Line 2
50 100 150 200 250
Fig. 2. Unsupervised hierarchical cluster analysis. The expression value (log2) for each detectable miRNA (Cq < 37) was used to determine
the clustering of the samples. Red: primary OS samples; yellow: OS cell lines; blue: OB cell lines.
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investigation of these 14 miRNAs in the OS discovery
cohort analyzed in this study showed that six of the
miRNAs did exhibit a differential expression in OS
samples when compared to OB cell lines, but no differ-
ence was observed between OS and OB cell lines; four
of the miRNAs did not exhibit a significant difference
between OS samples and OB cell lines, and four miR-
NAs were not present in our normalized data set.
3.3. Validation of differentially expressed miRNAs
The 33 miRNAs identified in the discovery cohort
were validated in a larger, independent cohort
consisting of 78 primary OS FFPE samples using a
custom-designed Pick&Mix microRNA PCR Panel.
Of the 26 miRNAs with decreased expression, 24
were confirmed in the validation cohort, and of the
seven miRNAs with increased expression, five were
confirmed, thereby corroborating 88% of our initial
findings (Table 2, Fig. 3 and Fig. S2A,B).
3.4. Pathways associated with the deregulated
miRNAs and their target genes
To determine the possible impact of the 29 differen-
tially expressed miRNAs on OS development, enriched
Table 2. Expression level of 33 significantly differentially expressed miRNAs in OS samples compared to OB cell lines.
miRNA
Discovery cohort Validation cohort
Fold changea P-value
No. OS sign.
changed (%) Fold changea P-value
No. OS sign.
changed (%)
Downregulated miRNAs
miR-100-5p 34.75 8.0 9 104 23 (100) 12.80 2.34 9 105 76 (97)
miR-221-3p 14.21 8.0 9 104 23 (100) 10.79 2.34 9 105 78 (100)
miR-29b-1-5p 16.45 8.0 9 104 23 (100) 17.44 2.34 9 105 78 (100)
miR-125b-1-3p 13.50 8.0 9 104 23 (100) 5.31 9.38 9 105 76 (97)
miR-29a-5p 33.65 8.0 9 104 23 (100) 3.60 9.38 9 105 72 (92)
miR-370-3p 14.89 0.0031 20 (87) 19.62 9.38 9 105 77 (99)
miR-299-5p 19.42 0.0015 22 (96) 24.42 2.0 9 104 76 (97)
miR-493-5p 25.62 0.0085 20 (87) 32.46 3.0 9 104 75 (96)
miR-409-3p 31.36 0.0015 22 (96) 19.60 4.0 9 104 71 (91)
miR-30e-3p 2.91 0.0015 21 (91) 2.78 0.0012 67 (86)
miR-431-5p 4.92 0.0031 19 (83) 16.77 0.0012 69 (88)
miR-432-5p 16.05 0.0031 22 (96) 22.79 0.0016 74 (95)
miR-410-3p 16.83 8.0 9 104 21 (91) 14.66 0.0019 70 (90)
miR-411-5p 36.54 8.0 9 104 22 (96) 14.47 0.0034 67 (86)
miR-376c-3p 23.90 0.0031 22 (96) 16.57 0.0056 61 (78)
miR-125b-5p 8.45 0.0015 22 (96) 4.06 0.0064 61 (78)
miR-335-5p 45.39 8.0 9 104 23 (100) 5.32 0.0064 64 (82)
miR-376a-3p 34.17 0.0085 21 (91) 15.79 0.0064 65 (83)
miR-382-5p 13.97 0.0054 21 (91) 10.53 0.0135 62 (79)
miR-154-5p 13.62 0.0085 20 (87) 9.04 0.0244 53 (68)
miR-222-3p 5.11 0.0123 19 (83) 2.49 0.0267 54 (69)
miR-92b-3p 3.19 0.0085 21 (91) 2.01 0.0267 58 (74)
miR-433-5p 4.16 0.0054 18 (78) 4.76 0.029 52 (67)
miR-127-3p 21.94 0.0054 22 (96) 7.72 0.04 60 (77)
miR-34a-3p 3.44 0.0085 17 (74) 2.99 0.0888 5 (5)
miR-136-5p 13.63 0.0315 21 (91) 2.72 0.248 35 (45)
Upregulated miRNAs
miR-181a-5p 12.04 8.0 9 104 23 (100) 8.38 2.34 9 105 78 (100)
miR-181c-5p 9.29 0.0015 20 (87) 15.24 2.34 9 105 60 (77)
miR-223-3p 727.23 8.0 9 104 23 (100) 859.9 2.34 9 105 78 (100)
miR-342-3p 12.84 0.0031 17 (74) 3.44 9.38 9 105 75 (96)
miR-378a-3p 4.20 0.0177 19 (83) 5.49 3.0 9 104 74 (95)
miR-128-3p 3.22 0.0015 22 (96) 1.06 0.9328 16 (21)
miR-181b-5p 4.19 0.0085 14 (61) 2.72 0.1051 25 (32)
Discovery cohort = 23 fresh-frozen OS samples; validation cohort = 78 FFPE OS samples; miRNAs in bold text = significantly differentially
expressed in both cohorts. No., number.
a Expression change between primary OS samples and OB cell lines.
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biological functions were explored using Ingenuity
Pathway Analysis (IPA) and DIANA Tools mir-
Path.v3 exploring KEGG pathways. Several biological
functions related to cancer development and progres-
sion were enriched for the 29 deregulated miRNAs
(Table 3).
Alterations in miRNA expression may have an
extensive effect on gene expression, as one miRNA
can directly or indirectly regulate more than 100 target
genes by binding to their 30UTR. Genes targeted by at
least one of the 29 differentially expressed miRNAs
were therefore identified using miRWalk2.0 analyzing
only experimentally validated target genes. Genome-
wide RNA expression changes in OS were established
by analyzing the 23 OS samples from the discovery
cohort with RNA expression microarrays containing
27958 Entrez Gene RNAs (Andersen et al., in prepara-
tion). The identified target genes were correlated with
genes identified as differentially expressed in the OS
samples compared to OB cell lines (> 2-fold change
and P-value < 0.05). This identified 301 genes with
upregulated expression in OS samples, targeted by one
or more of the identified downregulated miRNAs, as
well as 60 genes with decreased expression in the OS
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
–10
–5
0
5
10
Ex
pr
es
si
on
 (l
og
2)
miR-100-5p
Discovery cohort Validation cohort
** **
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-370-3p
* **
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-181a-5p
** **
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-125b-5p
* *
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-335-5p
** *
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-181c-5p
* **
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-127-3p
* *
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-411-5p
** *
Discovery cohort Validation cohort
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
OS
 sa
mp
les
OB
 ce
ll l
ine
s
OS
 ce
ll l
ine
s
miR-223-3p
** **
Discovery cohort Validation cohort
Downregulated miRNAs
Upregulated miRNAs
Fig. 3. Boxplots of the expression of nine differentially expressed miRNAs. Red: OS samples. *P < 0.05; **P < 0.001.
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samples targeted by one or more of the miRNAs with
increased expression in the OS samples (Table S5).
The possible influence of the deregulation of
miRNA expression on OS development, associated
with the affected target genes, was investigated using
IPA and KEGG pathway analysis. The most signifi-
cant pathways, as well as biological functions associ-
ated with disease and cellular functions for validated
target genes, are reported in Table 4. For IPA, six of
the top ten biological functions and three of the top
five pathways were associated with cancer development
and progression. Furthermore, one of the biological
functions, for which deregulated genes were enriched,
was ‘Skeletal Disorders’ and one of the top canonical
pathways was ‘Role of Osteoblasts, Osteoclasts, and
Chondrocytes in Rheumatoid Arthritis’. For the
KEGG analysis, nine of the ten highest-ranking path-
ways were related to cancer development and progres-
sion. The 27th pathway for the KEGG analysis was
‘Osteoclast Differentiation’, thereby linking bone cell
biology and cancer development and progression for
the target genes with altered gene expression.
An analysis of the biological relations between the
target genes identified a network of 21 upregulated
Table 3. Biological functions associated with the 29 deregulated
miRNAs in OS. (A) IPA biological functionsa and (B) KEGG
pathwaysb identified by DIANA miRPath.v3
(A) P-value
No. of
miRNAs
associated
Diseases and disorders
Cancerc 4.14 9 1013 18
Connective tissue disorders 4.14 9 1013 12
Organismal injury and abnormalities 4.14 9 1013 20
Reproductive system disorders 8.23 9 109 15
Developmental disorder 4.49 9 108 6
Molecular and cellular functions
Cell death and survivalc 2.84 9 104 5
Cell-to-cell signaling and interactionc 0.00342 1
Cellular developmentc 0.00342 6
Cellular growth and proliferationc 0.00570 6
Cell cyclec 0.0125 1
(B)
Pathway P-value
No. of
miRNAs
associated
Proteoglycans in cancerc 2.93 9 1013 20
Prion diseases 1.52 9 1010 15
ECM/receptor interactionc 9.02 9 1010 20
Other types of O-glycan biosynthesis 6.83 9 108 13
Hippo signaling pathwayc 1.49 9 107 20
Gliomac 5.18 9 106 19
Signaling pathways regulating
pluripotency of stem cellsc
5.18 9 106 21
Steroid biosynthesis 5.38 9 106 9
Mucin-type O-glycan biosynthesis 9.70 9 106 14
Transcriptional misregulation in cancerc 2.95 9 105 21
a Diseases and molecular functions associated with the 29 deregu-
lated miRNAs identified by IPA.
b KEGG pathways associated with the 29 deregulated miRNAs
identified by DIANA miRPath.v3.
c Association with cancer development and progression.
Table 4. Pathways and biological functions associated with genes
targeted by deregulated miRNAs.
IPA canonical pathways P-value
Atherosclerosis signaling 5.60 9 107
Role of NANOG in mammalian embryonic stem
cell pluripotencya
2.53 9 106
Role of osteoblasts, osteoclasts, and
chondrocytes in rheumatoid arthritisb
5.59 9 106
Role of tissue factor in cancera 1.41 9 105
Natural killer cell signalinga 1.53 9 105
IPA biological functions P-value
No. of
genes
associated
Diseases and disorders
Connective tissue disorders 2.86 9 1013 77
Inflammatory disease 2.86 9 1013 91
Organismal injury and abnormalities 2.86 9 1013 348
Skeletal and muscular disordersb 2.86 9 1013 104
Cancera 4.66 9 1011 343
Molecular and cellular functions
Cellular growth and proliferationa 1.28 9 1011 121
Cellular movementa 1.70 9 1010 80
Cellular Developmenta 1.05 9 109 86
Cell-to-cell signaling and interactiona 5.07 9 108 60
Cell death and survivala 6.10 9 107 102
KEGG pathways
No. of genes
associated
Metabolic pathwaysa 22
MAPK signaling pathwaya 17
Pathways in cancera 16
Cytokine/cytokine receptor interactiona 14
PI3K-Akt signaling pathwaya 14
Ras signaling pathwaya 14
Proteoglycans in cancera 13
Regulation of actin cytoskeletona 12
Rap1 signaling pathway 12
MicroRNAs in cancera 11
IPA and KEGG analysis of the 301 upregulated and 60 downregu-
lated genes identified to be targeted by the 29 deregulated miR-
NAs.
a Association with cancer development and progression.
b Association with bone cell biology.
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and eight downregulated genes significantly associated
with ‘Cell Death and Survival, Cancer, Hematological
System Development and Function’ (P-value = 1042).
The intimate relationship of the 29 genes and the seven
downregulated and four upregulated miRNAs vali-
dated to target these genes is illustrated in Fig. 4. The
identified network comprised five genes (CCNG1,
MDM2, TNFSF10, TP53, and UCHL1) directly asso-
ciated with the TP53 pathway. Three additional target
genes (ABL1, FASLG, and UBD) not part of the iden-
tified network were associated with the TP53 pathway.
Four target genes (ABL1, MDM2, STMN1, and
TP53) were associated with the RB pathway.
3.5. miRNAs associated with the metastatic
status and response to chemotherapy
To identify miRNAs with an overall difference in
expression based on the metastatic status, the discov-
ery cohort was separated into metastatic and non-
metastatic primary OS (8 and 15 OS samples,
respectively). This analysis revealed three miRNAs
(miR-29b-3p, miR-29c-3p, and miR-374a-5p)
significantly differentially expressed between metastatic
and nonmetastatic OS samples (Table S9 and Fig. S3).
The response to neoadjuvant chemotherapy was ana-
lyzed by subdividing the discovery cohort into poor
responders (< 90% necrosis after chemotherapy) and
good responders (> 90% necrosis after chemotherapy)
(8 and 9 OS samples, respectively). This identified
miR-663b as significantly differentially expressed. Also,
miR-664a-3p showed a strong trend toward differential
expression (Table S9 and Fig. S3). However, when
these miRNAs were analyzed in the samples from the
validation cohort, none of the three miRNAs associ-
ated with the metastatic status nor the two miRNAs
associated with the chemotherapeutic response dis-
played a significant difference (Table S9 and Fig. S3).
3.6. Prognostic value of the 29 differentially
expressed miRNAs
The only prognostic markers for OS are currently
absence of metastases at the time of diagnosis and
response to chemotherapy. As 25–30% of OS patients
develop distant metastases and the five-year survival
Fig. 4. Network of validated target genes. Network of validated target genes associated with the terms ‘Cell Death and Survival, Cancer,
Hematological System Development and Function’. The relation of 29 validated target genes (miRWalk2.0) assembled in a network
associated with 11 miRNAs altered in OS in this study. Eight genes were downregulated and 21 upregulated. Red: downregulated; blue:
upregulated. Gray lines: association between genes; Red lines: association between gene and miRNA; continuous line: direct association;
dashed line: indirect association.
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rate for patients with relapse is only 10–40%, it is crit-
ical to identify new prognostic biomarkers for OS.
We therefore investigated the prognostic value in
function of survival and time to development of meta-
static disease of the 29 differentially expressed miR-
NAs. Kaplan–Meier analysis was performed on the
discovery cohort divided into two groups based on the
median expression (high and low expression groups for
each miRNA). For the overall survival analysis, two
miRNAs (miR-128-3p and miR-34a-3p) were border-
line significant in the discovery cohort (P = 0.0880 and
0.0760, respectively). No significant difference was,
however, observed in the larger OS cohort (P = 0.5645
and 0.7507, respectively).
Analysis of the miRNA expression in function of
time to metastasis, describing the aggressiveness of the
OS tumor, identified miR-222-3p and miR-221-3p as
significantly (P = 0.0359) and borderline significantly
(P = 0.0863) associated with time to metastasis in the
discovery cohort, respectively (Fig. S4A,C). High
expression of miR-221-3p and low expression of miR-
222-3p correlated with a poor prognostic value and
earlier development of distant metastases. The associa-
tion between expression level and poor prognosis in
terms of earlier development of distant metastases was
highly significant in the validation cohort (P = 0.0065
and 0.0074, respectively) (Fig. S4B,D) and when com-
bining results from both the discovery and validation
cohorts (P = 0.0007 and 0.0015, respectively) (Fig. 5A,
B). When combining the expression level of the two
miRNAs into one prognostic signature, there was a
clear separation between OS patients with low-miR-
221-3p/high-miR-222-3p expression and OS patients
with high-miR-221-3p/low-miR-222-3p for both the
discovery and validation cohorts and in combination
(P = 2.4 9 108) (Fig. 5C and Fig. S4E,F).
4. Discussion
OS is a complex disease exhibiting alterations in
numerous pathways and with major cell-to-cell varia-
tion. The understanding of the etiology of OS is lim-
ited and no common molecular alteration has been
identified. This designates the need for a more
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fundamental understanding of the underlying mecha-
nisms leading to OS development and progression.
Alterations in miRNA expression are one of the mech-
anisms associated with tumor development. As one
miRNA potentially regulates the expression of more
than 100 target genes, alterations in miRNA expres-
sion can have a vast impact on neoplastic initiation
and progression. Hence, the focus of this study was
the analysis of miRNA expression changes in OS. Pro-
filing of miRNA expression in OS has been addressed
in previous studies (Duan et al., 2011; Jones et al.,
2012; Lulla et al., 2011; Maire et al., 2011; Namlos
et al., 2012; Thayanithy et al., 2012; Won et al., 2013;
J. Zhang et al., 2015). However, the limited number of
samples of 2–18 OS samples in the discovery cohorts
and 2–12 samples in the respective validation cohorts
makes it challenging to draw reliable conclusions from
the published data.
We have in this study investigated the expression of
752 miRNAs in 23 OS samples and validated signifi-
cant findings in 78 additional OS samples. These are,
to our knowledge, both the largest discovery and vali-
dation cohorts so far used for miRNA expression
analysis in OS. The identified miRNA expression sig-
nature showed strong statistical significance in both
the discovery and the validation cohorts comprising
together a total of 101 OS samples. This provides
robust evidence of the 29 miRNAs with an altered
expression level between OS samples and OB cell lines
to be truly deregulated in OS. A difference in miRNA
expression between histological subtypes was not iden-
tified designating a universal role of the deregulated
miRNAs in OS tumorigenesis.
A significant role of miRNAs in OS tumorigenesis
was supported by the investigation of biological func-
tions associated with the 29 deregulated miRNAs,
revealing a strong correlation with cancer development
and progression. This was further substantiated by the
investigation of the validated miRNA/mRNA targets,
identifying 361 genes with a significantly changed
expression level in the OS samples. These genes were
associated with multiple pathways and biological func-
tions related to cancer development and progression.
Furthermore, both a canonical pathway and biological
functions were associated with bone cell pathogenesis
linking the cancer-related pathways with OS tumorige-
nesis.
A relation between the identified pathways associ-
ated with the target genes and the TP53 pathway,
which is often altered in OS, also supported a correla-
tion between the deregulated miRNAs and OS tumori-
genesis. The network analysis and target genes
comprised a total of eight genes directly associated
with the TP53 pathway (ABL1, CCNG1, FASLG,
MDM2, TNFSF10, TP53, UBD, and UCHL1) and
four genes (ABL1, MDM2, STMN1, and TP53) asso-
ciated with the RB pathway. Hence, the altered miR-
NAs identified in this study fit well with the current
view of OS pathogenesis that the TP53 and RB path-
ways are the two major pathways involved in OS
development and progression. Many potential func-
tional miRNA/mRNA relationships were identified in
this study. These need to be further investigated to
determine their function and involvement in OS
tumorigenesis.
The prognostic value of the 29 deregulated miRNAs
was also investigated in function of the overall survival
and time to metastasis by subdividing the OS samples
into high/low expression groups. This identified two
miRNAs, miR-221-3p and miR-222-3p, in which the
expression level showed a significant association with
time to metastasis. When combining the high/low
expression scores for the two miRNAs for each OS
patient, the separation became even more distinct and
significant, signifying the robustness of the miR-221/
222 signature as a prognostic biomarker. Increased
expression of miR-221 and miR-222 has also been
shown to be significantly associated with lymphatic
metastasis in gastric, colorectal, and breast cancer
(Falkenberg et al., 2013; Fu et al., 2014; Liu et al.,
2012b; Sun et al., 2011). Furthermore, these two miR-
NAs have been shown to be a promising biomarker in
breast cancer in function of time to developing distant
metastasis, although a high expression of both miR-
NAs was associated with poor prognosis in breast can-
cer (Falkenberg et al., 2013). The discrepancy of miR-
222 expression between these studies and the OS sam-
ples in this study may be explained by the ability of a
miRNA to target several hundred genes, thereby pro-
moting tumor growth in some malignancies and
repressing it in others. This is further substantiated by
the fact that miR-222 was shown to target MMP1,
which is associated with increased aggressiveness and
metastatic risk in oral tongue squamous cell carcinoma
(Liu et al., 2009) (MMP1 showed a 10-fold increase in
expression in the OS samples in this study). High
expression of MMP1 has also been associated with the
development of metastasis in colorectal and breast
cancer (Liu et al., 2012a; Sunami et al., 2000). miR-
221 targets among other genes BCL2L11, which exhi-
bits pro-apoptotic properties, thereby suppressing
tumor growth (Aichberger et al., 2009), as well as the
gatekeeper PTEN (Li et al., 2016). In different cancers,
high expression of miR-221/222 has also been shown
to facilitate epithelial/mesenchymal transition, a pre-
requisite for metastasis formation (Li et al., 2015;
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Stinson et al., 2011). Furthermore, modulation of
miR-221 levels in OS cell lines demonstrated its role in
carcinogenesis with high levels leading to increasing
invasiveness and migration of the cells (Zhu et al.,
2015). Hence, both the deregulation itself and the tar-
get genes of miR-221 and miR-222 indicate a promi-
nent role of these two miRNAs in the ability of a
neoplasm to spread to other organs and in the aggres-
siveness of specific cancer types.
Of the 29 deregulated miRNAs identified in this
study, expression changes in nine miRNAs have not
previously been associated with OS in miRNA profil-
ing studies, while 20 miRNAs previously associated
with OS development and progression were uncovered
(Duan et al., 2011; Jones et al., 2012; Lulla et al.,
2011; Maire et al., 2011; Namlos et al., 2012; Thaya-
nithy et al., 2012; Won et al., 2013; Zhang et al.,
2015). However, as OS is characterized by many differ-
ent alterations, confirmation of previous findings is
important for this particular disease. Furthermore,
many of the formerly reported miRNA changes in OS
have been identified in cohorts comprising less than 10
OS samples. Previous studies profiling miRNA expres-
sion changes in OS revealed 14 miRNAs significantly
changed in these studies, which were not among the 29
miRNAs identified in our study. This may be due to
differences in the cohorts, but also due to low sample
number in the published studies or the use of normal
bone as the control tissue, comprising a lower number
than the OS cohorts (comprising 2–12 normal bone
samples) (Jones et al., 2012; Namlos et al., 2012;
Thayanithy et al., 2012; Won et al., 2013; Zhang
et al., 2015). The cell of origin for OS has not yet been
completely clarified. Both mesenchymal stem cells
(MSCs) and derived osteoprogenitors such as OBs
have been analyzed for their ability to form OS. Sev-
eral studies have shown that OB precursors presented
a higher incidence of OS compared to early mesenchy-
mal progenitors (Abarrategi et al., 2016), supporting
the model of OS originating from cells with OB com-
mitment rather than immature MSCs. OB cell lines
have therefore been used as the normal controls in this
study, as well as in several previous studies (compris-
ing 1–3 OB cell lines) (Duan et al., 2011; Lulla et al.,
2011; Maire et al., 2011). Only one study has so far
been using both normal bone tissue and OB cell lines
as controls, but analyzed only 15 miRNAs previously
identified to be differentially expressed between normal
bone and OS cell lines. Nine of these were validated in
primary OS samples when compared to normal bone.
However, for some of these miRNAs, the authors
observed opposite expression changes in OS when
compared to either OB cell lines or normal bone
(Namlos et al., 2012). This may be due to OS being at
an intermediate state between the undifferentiated OB
cells and the fully differentiated bones comprising sev-
eral different cell types. Furthermore, normal bone
was obtained from cancer patients suggesting a differ-
ent age distribution between OS samples and bone
samples, which could lead to differential miRNA
expression profiles, and raise the question of the possi-
ble presence of cancer-related epigenetic alterations in
these samples. These points, as well as the small num-
ber of miRNAs analyzed in primary OS, bone and OB
cell lines, make it difficult to draw general conclusions
from this study. Even though OB cells can be consid-
ered to be the cell of origin of OS, the use of cell lines
as normal control holds the limitation of identifying
miRNAs with altered expression due to differences
between cell lines and human tissue and not due to the
cell origin. Unfortunately, no normal bone tissue was
available for the current study. Therefore, future stud-
ies should comprise pediatric OB cells as normal con-
trol as well as normal bone to obtain a more
comprehensive description of the role of the identified
miRNAs in OS tumorigenesis.
Several of the 24 significantly downregulated miR-
NAs identified in this study have previously been iden-
tified as tumor suppressor miRNAs in other
malignancies, among others miR-100-5p, miR-125b-5p,
miR-127-3p, miR-370-3p, miR-335-5p, and miR-411-
5p (Gao et al., 2016; He et al., 2013; Jiang et al.,
2014; Li et al., 2014; Luan et al., 2016; Zhang et al.,
2016). Of these, miR-100-5p, miR-127-3p, and miR-
335-5p have previously been identified as downregu-
lated in OS studies analyzing 2–18 samples (Jones
et al., 2012; Maire et al., 2011; Thayanithy et al.,
2012; Zhang et al., 2015). However, miR-127-3p and
miR-370-3p have also been detected upregulated in
two OS samples in one study (Zhang et al., 2015).
miR-125b-5p and miR-411-5p have not previously
been identified having an altered expression in any OS
miRNA profiling studies. miR-125b has been shown to
be an important regulator of both proliferation and
differentiation in different cell types (Scott et al., 2007;
Sempere et al., 2004). Moreover, miR-125b has been
shown to inhibit normal OB proliferation in mouse
cells (Mizuno et al., 2008), indicating a role of this
miRNA in bone development and thereby in OS
tumorigenesis. miR-335-5p has also been identified to
be important in the differentiation process of bone
cells, as a positive regulator of Wnt signaling through
the inhibition of Wnt antagonists (Zhang et al., 2011).
Wnt signaling is elevated when osteoprecursor cells
differentiate into OBs. However, Wnt signaling is
inhibited when the OB cells differentiate further
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toward the terminal stage of bone-forming cells, which
may be a functional explanation for the downregula-
tion of miR-335-5p in OS.
Of the five significantly upregulated miRNAs identi-
fied in this study, miR-181a-5p, miR-181c-5p, miR-
223-3p, and miR-342-3p have been described as onco-
miRs in other cancer types (Mi et al., 2017; Tao et al.,
2014; Walter et al., 2013; Wei et al., 2014). Of these,
miR-181a-5p, miR-181c-5p, and miR-223-3p have pre-
viously been identified as upregulated in 4–18 OS sam-
ples (Jones et al., 2012; Lulla et al., 2011; Maire et al.,
2011; Won et al., 2013). However, miR-223-3p has
also been detected as downregulated in 18 OS samples
in one study (Jones et al., 2012). miR-342-3p has not
previously been associated with OS in miRNA profil-
ing studies. miR-181a-5p has been shown to downreg-
ulate a Wnt antagonist, thereby activating the Wnt
signaling, which is, as described above, important for
the differentiation of osteoprecursor cells into OB cells
(Lyu et al., 2017).
Future functional studies for each identified miRNA
and their target genes in OS development and progres-
sion have a strong potential for discovering novel diag-
nostic and prognostic markers as well as developing
new treatment strategies, thereby improving the long-
term survival rate for these young patients. Circulating
miRNAs detected in serum and plasma of patients
with cancer are being widely investigated for their
potential as both diagnostic and prognostic markers of
cancer, including OS (Ram Kumar et al., 2016). This
might also provide a tool of diagnosing OS at an ear-
lier time point when individuals complain repeatedly
about ‘growing’ pains. Furthermore, miRNAs hold the
promise of novel therapeutic targets, either by block-
ing the expression of an oncomiR or by substituting
the loss of a tumor suppressor miRNA.
5. Conclusion
In conclusion, this study substantiates the importance
of miRNA deregulation in OS and its association with
OS tumorigenesis. We have identified and validated 29
deregulated miRNAs in, to our knowledge, the largest
discovery and validation cohorts published, comprising
a total of 101 OS samples. Both the miRNAs and their
identified target genes are associated with multiple
pathways and biological functions, related to cancer
development and progression, as well as bone cell biol-
ogy, thereby associating the deregulated miRNAs with
OS tumorigenesis. Interestingly, a promising potential
as prognostic biomarkers for the aggressiveness of OS
was seen for two of these miRNAs (miR-221-3p and
miR-222-3p).
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